NCI 2026 Cervical Cancer Screening Follow-Upview on SAM.gov

Small Business Sources Sought Notice NCI 2026 Cervical Cancer Screening Follow-Up NCI-SBSS-DCEG-TDRP-0001 This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether there are small businesses; HUBZone small businesses; veteran owned small businesses; service-disabled veteran-owned small businesses; 8(a) small businesses; woman-owned small businesses; or small disadvantaged business; and (3) their size classification relative to North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. NAICS Code and Size Standard: The primary NAICS code for this acquisition is 622110- General Medical and Surgical Hospitals, which has a size standard of $47million. All businesses may submit a capability statement; however, a statement should be included indicating whether the company is considered a small business under the above NAICS code. A determination by the Government not to compete this requirement as a set-aside based upon responses to this notice is solely within the discretion of the Government. Interested parties are expected to review this notice and the draft Statement of Work (SOW) to familiarize themselves with the requirements of this project; failure to do so will be at your firm's own risk. Background: Despite Human Papillomavirus (HPV) vaccines, screening will remain central for decades to control cervical cancer. Recently, HPV testing alone or with cytology was introduced in the US as an alternative to cytology screening. However, most HPV infections are harmless, and additional tests are required to identify women at highest cancer risk. The National Cancer Institute (NCI) has analyzed data for over 1.5 million women screened for cervical cancer at Kaiser Permanente Northern California (KPNC) clinics. In addition, National Cancer Institute (NCI) has funded previous studies conducted at Kaiser Permanente Northern California to collect biospecimens for biomarker testing and to study risk estimates for cervical cancer screening. To continue these efforts and generate long-term risk estimates, follow-up, de-identified clinical data from participants in these studies is required. Purpose and objectives: The NCI will follow the status of women undergoing cervical cancer screening at KPNC. This follow-up requires the Contractor to provide detailed clinical and risk factor history and follow-up data for women enrolled in previous studies, including de-identified data on the status of women undergoing cervical cancer screening at KPNC. This acquisition will collect the results of all Human Papillomavirus (HPV) and cytology-based testing as well…